期刊文献+

霉酚酸酯治疗难治性狼疮肾炎的临床研究 被引量:2

Clinical investigation of mycophenolate mofetil treatment for refractory lupus nephritis
原文传递
导出
摘要 目的探讨霉酚酸酯(MMF)对难治性狼疮肾炎(LN)的疗效。方法观察38例环磷酰胺冲击治疗无效、复发或因毒副反应停药的难治性LN者MMF治疗12个月的疗效及活动指标变化。结果浮肿、关节肿痛、皮疹、血白细胞减低的病例在治疗个月后显著减少,个月后消失。治疗前136个月尿蛋白、血沉、血尿素氮、血肌酐和抗dsDNA抗体显著降低,血白蛋白显著增加;6个月后这些变化趋缓。16例肾功能不全者治疗个月,例(61488%)肾功能恢复正常。在MMF治疗中C3逐步升高、抗核抗体(ANA)逐步下降,变化有统计学意义;C4在治疗12个月后较治疗前有显著升高。毒副反应发生率24%,显著低于治疗前74%。结论MMF对难治性LN有显著疗效且毒副作用小,其疗效变化可能与剂量有关。 Objective To investigate the effects of mycophenolate mofetil (MMF) treatment for refractory lupus nephritis (LN). Methods Thirty eight patients with LN, who had failed intermittent cyclophosphamide (CTX) intravenous treatment or had relapsed or to withdraw because of adverse reactions, had received the MMF treatment for 12 months. The clinical efficacy and immunology indexes were assessed. The dosage of MMF was decreased after treated for 6 months. Results The cases with edema, arthralgia,skin rashes,anemia, low white blood cell and blood urine after one month of MMF treatment were significantly less than that before treatment. Edema, arthralgia, skin rashes and low white blood cell disappeared after 3 months of treatment. During the first 6 month of MMF treatment, urine protein, erythrocyte sedimentation rate, blood urea nitrogen and blood creatinine were significantly reduced, anti-dsDNA antibody titer decreased gradually, serum albumin increased, but the changes became slower after 6 months. The renal function of 14 cases (88%) in 16 patients with renal failure recovered after 6 months of MMF treatment. During MMF treatment serum complement 3 increased and anti-nucleus antidodies decreased, serum complement 4 increased significantly after treatment for 12 months. The difference, compared with that of before treatment, was significant. The incidence of adverse effects of MMF treatment was less than before treatment (24% vs 74%). Conclusion MMF treatment for refractory LN is effective with few side-effects. The efficacy may be dose dependent.
出处 《中华风湿病学杂志》 CAS CSCD 2005年第2期102-105,共4页 Chinese Journal of Rheumatology
关键词 霉酚酸酯 治疗 难治性狼疮肾炎 临床研究 Mycophenolic acid Lupus nephritis Treatment effect
  • 相关文献

参考文献10

二级参考文献23

  • 1Austin HA. Therapy of lupus nephritis: controlled trial of prednisone and cytoxic drugs. New Engl J Med, 1986, 314:614-619.
  • 2Vasquez S, Kavanaugh AF, Schneider NR, et al. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol,1992, 19: 1625.
  • 3Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis, 1998, 32: 318-322.
  • 4Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 2000,343: 1156-1162.
  • 5Cameron JS. Lupus nephritis. J Am Soc Nephrol, 1999, 10: 413.
  • 6Dooley MA, Cosio FG, Patrick H, et al. Mycophenolate mofetiltherapy in lupus nephritis: clinical observations. J Am Soc Nephrol, 1999, 10: 833-839.
  • 7Layne D. Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens, 1999, 8: 563.
  • 8Ziswiler R,Steinmann-Niggli K,Kappele A,et al.Mycophenolic acid:a new approach to the therapy of experimental mesangial proliferative glomerulonephritis.J Am Soc Nephrol,1998,9:2055-2066.
  • 9Tan EM,Cohen AS,Fries JF,et al.The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum,1982,25:1271-1277.
  • 10Fulton B,Markham A.Mycophenolate mofetil:a review of its pharmacodynamic and pharmcokinetic properties and clinical efficacy in renal transplantation.Drug,1996,51:278-298.

共引文献95

同被引文献24

  • 1沈慕群.男性和女性狼疮性肾炎临床对比观察[J].海南医学,2005,16(5):7-8. 被引量:2
  • 2王彩丽,刘玉春,王海燕,潘缉圣,邹万忠,金其庄.男性狼疮性肾炎50例临床与病理分析[J].中华内科杂志,1995,34(12):827-830. 被引量:26
  • 3Steinberg AD,Steinberg SC.Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only[J].Arthritis Rheum,1991,34:945-950.
  • 4Boumpas DT,Austin HA III,Fessler BJ,et al.Systemic lupus erythematosus:emerging concepts.Part I.Renal,neuropsychiatric,cardiovascular,pulmonary,and hematologic disease[J].Ann Intern Med,1995,122:940-950.
  • 5Austin HA III,Klippel JH,Balow JE,et al.Therapy of lupus nephritis:controlled trial of prednisone and cytotoxic drugs[J].N Engl J Med,1986,314:614-619.
  • 6Valeri A,Radhakrishnan J,Estes D,et al.Intravenous pulse cyclophosphamide treatment of severe lupus nephritis:a prospective five-year study[J].Clin Nephrol,1994,42:71-78.
  • 7Lehman TJ,Sherry DD,Wagner-Weiner L,et al.Intermittent intravenous cyclophosphamide therapy for lupus nephritis[J].J Pediatr,1989,114:1055-1060.
  • 8Boumpas DT,Austin HA III,Vaughn EM,et al.Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis[J].Lancet,1992,340:741-745.
  • 9Korbet SM,Lewis EJ,Schwartz MM,et al.Factors predictive of outcome in severe lupus nephritis[J].Am J Kidney Dis,2000,35:904-914.
  • 10Gourley MF,Austin HA III,Scott D,et al.Methylprednisolone and cyclophosphamide,alone or in combination,in patients with lupus nephritis[J].Ann Intern Med,1996,125:549-557.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部